Revvity Management

Management criteria checks 4/4

Revvity's CEO is Prahlad Singh, appointed in Jan 2019, has a tenure of 5.25 years. total yearly compensation is $9.13M, comprised of 11.9% salary and 88.1% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $12.93M. The average tenure of the management team and the board of directors is 5.3 years and 6.5 years respectively.

Key information

Prahlad Singh

Chief executive officer

US$9.1m

Total compensation

CEO salary percentage	11.9%
CEO tenure	5.3yrs
CEO ownership	0.1%
Management average tenure	5.3yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27

Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

Dec 12

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

Nov 14

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

Nov 08

PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

Oct 28

PerkinElmer declares $0.07 dividend

Oct 27

CEO Compensation Analysis

How has Prahlad Singh's remuneration changed compared to Revvity's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$9m	US$1m	US$180m
Oct 01 2023	n/a	n/a	US$213m
Jul 02 2023	n/a	n/a	US$250m
Apr 02 2023	n/a	n/a	US$353m
Jan 01 2023	US$11m	US$1m	US$513m
Oct 02 2022	n/a	n/a	US$599m
Jul 03 2022	n/a	n/a	US$637m
Apr 03 2022	n/a	n/a	US$694m
Jan 02 2022	US$10m	US$1m	US$889m
Oct 03 2021	n/a	n/a	US$1b
Jul 04 2021	n/a	n/a	US$1b
Apr 04 2021	n/a	n/a	US$1b
Jan 03 2021	US$9m	US$900k	US$631m
Oct 04 2020	n/a	n/a	US$412m
Jul 05 2020	n/a	n/a	US$294m
Apr 05 2020	n/a	n/a	US$226m
Dec 29 2019	US$4m	US$645k	US$228m
Sep 29 2019	n/a	n/a	US$235m
Jun 30 2019	n/a	n/a	US$251m
Mar 31 2019	n/a	n/a	US$247m
Dec 30 2018	US$2m	US$517k	US$237m
Sep 30 2018	n/a	n/a	US$128m
Jul 01 2018	n/a	n/a	US$149m
Apr 01 2018	n/a	n/a	US$147m
Dec 31 2017	US$2m	US$464k	US$157m

Compensation vs Market: Prahlad's total compensation ($USD9.13M) is below average for companies of similar size in the US market ($USD13.53M).

Compensation vs Earnings: Prahlad's compensation has been consistent with company performance over the past year.

CEO

Prahlad Singh (58 yo)

5.3yrs

Tenure

US$9,130,624

Compensation

Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of Revvity, Inc. (formerly known as PerkinElmer, Inc.) since December 30, 2019. Dr. Singh served as the Chairman of the Supervisory Board at E...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Prahlad Singh	CEO, President & Director	5.3yrs	US$9.13m	0.10% $ 12.9m
Maxwell Krakowiak	Senior VP & CFO	1.7yrs	US$2.75m	0.0026% $ 326.0k
Tajinder Vohra	Senior Vice President of Global Operations	6.3yrs	US$1.76m	0.021% $ 2.7m
Joel Goldberg	Senior VP of Administration	15.8yrs	US$2.64m	0.085% $ 10.6m
Miriame Victor	Senior VP & Chief Commercial Officer	3.3yrs	US$1.70m	0.0072% $ 896.5k
Andrew Okun	VP, Chief Accounting Officer & Treasurer	13yrs	no data	0.00053% $ 66.5k
Arvind Sundar-Rajan	Vice President of Digital & Technology	no data	no data	no data
Madhuri Hegde	Senior VP & Chief Scientific Officer	no data	no data	no data
Jayashree Thacker	Senior VP & Global Chief Information Officer	no data	no data	no data
Stephen Willoughby	Senior VP of Investor Relations & Head of ESG	no data	no data	no data
Magali Four	Senior VP & Chief People and Culture Officer	no data	no data	no data
Robert Friel	Advisor	4.3yrs	US$16.48m	no data

5.3yrs

Average Tenure

54yo

Average Age

Experienced Management: RVTY's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Prahlad Singh	CEO, President & Director	4.7yrs	US$9.13m	0.10% $ 12.9m
Alexis Michas	Independent Non-Executive Chairman	23.3yrs	US$474.38k	0.052% $ 6.6m
Sylvie Gregoire	Independent Director	9.2yrs	US$290.07k	0.016% $ 2.0m
Peter Barrett	Independent Director	12.2yrs	US$313.55k	0.017% $ 2.1m
Franklin Witney	Independent Director	7.8yrs	US$295.07k	0.013% $ 1.6m
Samuel Chapin	Independent Director	7.5yrs	US$315.07k	0.012% $ 1.5m
Sophie Vandebroek	Independent Director	less than a year	no data	0.00021% $ 26.3k
Pascale Witz	Independent Director	6.5yrs	US$290.07k	0.0067% $ 843.9k
Michel Vounatsos	Independent Director	4.1yrs	US$305.07k	0.0051% $ 640.7k
Michael Klobuchar	Independent Director	less than a year	no data	0.00021% $ 26.3k
Michelle McMurry-Heath	Independent Director	1.8yrs	US$290.07k	0.0016% $ 204.4k

6.5yrs

Average Tenure

61yo

Average Age

Experienced Board: RVTY's board of directors are considered experienced (6.5 years average tenure).

Revvity Management

Management criteria checks 4/4

Key information

Recent management updates

CEO, President & Director notifies of intention to sell stock

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Insider notifies of intention to sell stock

Insufficient new directors

Insider notifies of intention to sell stock

Recent updates

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Now 22% undervalued after recent price drop

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

Consensus EPS estimates increase by 42%, revenue downgraded

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

First quarter 2023 earnings: EPS exceeds analyst expectations

Insider notifies of intention to sell stock

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Consensus EPS estimates fall by 15%

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023